Re‐analysis of stratified samples of diverse liver diseases from GSE89377 and GSE6764 further supported a potential role for SF3B4 as a key driver in HCC progression (Figure 5C).[22] In support of our hypothesis, circAtlas 2.0 (January 2024 snapshot, Figure S4C, Supporting Information) predicted SF3B4 binding within the flanking region of circSMEK1. This evidence concerns the gene SF3B4 and liver disorder.